# Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

Study · id `cardio:ct-nct06006689` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06006689](<https://clinicaltrials.gov/study/NCT06006689>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06006689

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 228 participants.

## Technical summary

Registry record NCT06006689. Randomized; quadruple masking; primary purpose treatment. Start 2023-09-15 (actual); primary completion 2025-04-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 228 participants (enrolled count; ClinicalTrials.gov record NCT06006689, source copy `cardio:ctgov-nct06006689-2026-10-23`, retrieved 2026-10-26)
- Started: 2023-09-15 (actual) (ClinicalTrials.gov record NCT06006689, source copy `cardio:ctgov-nct06006689-2026-10-23`, retrieved 2026-10-26)
- Primary completion: 2025-04-16 (actual) (ClinicalTrials.gov record NCT06006689, source copy `cardio:ctgov-nct06006689-2026-10-23`, retrieved 2026-10-26)
- Completion: 2025-04-16 (actual) (ClinicalTrials.gov record NCT06006689, source copy `cardio:ctgov-nct06006689-2026-10-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06006689, source copy `cardio:ctgov-nct06006689-2026-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06006689-2026-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)
- Condition: Diabetic Kidney Disease
- Intervention (Drug): Qishen Yiqi Dripping Pills placebo 3 bags
- Intervention (Drug): Low dose Qishen Yiqi Dripping Pills 3 bags
- Intervention (Drug): High dose Qishen Yiqi Dripping Pills 3 bags
- Lead sponsor: Tasly Pharmaceutical Group Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Tasly Pharmaceutical Group Co., Ltd (`cardio:org-tasly-pharmaceutical-group-co-ltd`)

## Provenance

Content hash: 8ef43fc8d0810c568bc6e9a8dff439f7b7fcb43690ee4941c2a08718ebea8498
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
